je.st
news
Tag: backs
US Justice Dept backs Nokia/Alcatel-Lucent deal
2015-06-18 02:00:00| Total Telecom industry news
Finnish vendor says 15.6 billion transaction still on course for completion in first half of 2016.
Glenhill Advisors Backs Off As GAMCO Gets Its Way With Pep Boys-Manny Moe and Jack
2015-06-17 22:01:28| Auto Parts - Topix.net
Along with its affiliated funds, Glenn J. Krevlin 's Glenhill Advisors has cut its stake in Pep Boys-Manny Moe and Jack by about 398,000 shares to 3.35 million shares, according to a recent SEC filing. The current holding represents 6.2% of the company's outstanding common stock and comprises about 2.80 million shares with sole voting and dispositive power and 553,100 shares with shared voting and dispositive power.
Tags: with
jack
advisors
backs
Glenhill Advisors Backs Off As GAMCO Gets Its Way With Pep Boys-Manny Moe and Jack
2015-06-17 17:42:41| Chemicals - Topix.net
Along with its affiliated funds, Glenn J. Krevlin 's Glenhill Advisors has cut its stake in Pep Boys-Manny Moe and Jack by about 398,000 shares to 3.35 million shares, according to a recent SEC filing. The current holding represents 6.2% of the company's outstanding common stock and comprises about 2.80 million shares with sole voting and dispositive power and 553,100 shares with shared voting and dispositive power.
Tags: with
jack
advisors
backs
Big shareholder backs drugmaker Mylan
2015-06-16 17:58:59| Biotech - Topix.net
Mylan's biggest shareholder is backing the generic drugmaker's plan to remain a stand-alone company as it fights a takeover bid from larger rival Teva Pharmaceutical. Abbott Laboratories also says it will vote its nearly 15 percent stake in Mylan in favor of that company's proposed Perrigo acquisition bid, which is valued at around $34 billion.
Tags: big
backs
shareholder
mylan
FDA panel backs Amgen cholesterol drug for some patients
2015-06-11 08:41:53| Biotech - Topix.net
" Federal health advisers said that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance. But as with their review of a similar drug a day earlier, the Food and Drug Administration experts stressed Wednesday that long-term results are needed to judge the drug's real benefit.
Tags: panel
drug
patients
backs
Sites : [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] next »